A 40-year-old male with colorectal cancer, with an unbalanced hypercaloric diet, attempted,
on his own initiative, to gain weight, without nutritional follow-up, during chemotherapy treatment
with oxaliplatin protocols, without pharmaceutical guidance. When initiating the new protocol,
with oxaliplatin/irinotecan combination therapy, he presented symptomatology suggestive of hepatic
injury during the administration of oxaliplatin. When performing a Magnetic Resonance Imaging of
the total abdomen, hepatic nodules were identified indicating lesions resulting from the chemotherapy
treatment, and blood tests indicated Aspartate Aminotransferase levels in 55 U/L and Alanine
Aminotransferase in 68 U/L. The patient underwent partial hepatectomy for the removal of the nodules
and was currently in clinical care, presenting a frame stable but non-therapeutic possibility. This
case highlights the importance of interaction among health professionals, reinforcing the need for
multiprofessional approaches to better patient response to antineoplastic treatment.
Keywords: Antineoplastic Agents, chemical and drug-induced liver injury, combination, drug therapy, drug-related side effects
and adverse reactions, hepatotoxicity, overnutrition, oxaliplatin.
Rights & PermissionsPrintExport